Organigram CEO isn’t worried about Curaleaf’s threat to top its Aurora bid

Organigram CEO James Yamanaka says in an exclusive interview that Aurora’s European medical business will drive growth, even as Curaleaf argues the C$7.80 deal is a bad one for Organigram shareholders.